Literature DB >> 29124493

Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma.

Nilesh Lomte1, Sanjeet Kumar1, Vijaya Sarathi2, Reshma Pandit1, Manjunath Goroshi1, Swati Jadhav1, Anurag R Lila1, Tushar Bandgar3, Nalini S Shah1.   

Abstract

The data in genotype-phenotype correlation in Indian von Hippel-Lindau (VHL) patients is limited. We have retrospectively studied 31 genetically proven VHL patients with pheochromocytoma/paraganglioma (PCC/PGL) from families and have reviewed the World literature on PCC/PGL in patients with large VHL deletions. Three patients had large deletions and 28 patients had other mutations [missense mutations in 25, 3 bp deletion in 2 and single bp duplication in one]. Unilateral PCC were significantly more common in patients with large VHL deletions whereas multiple PCC (bilateral PCC or PCC + sympathetic PGL) were significantly more common in those with other mutations. World literature review confirmed the rarity of PCC/PGL in patients with large deletions and we report the first definitive case of PCC associated with complete VHL deletion. Pancreatic neuroendocrine tumours were more common, often metastatic and the most common cause of death in our cohort. Our study had eight parent off-spring pairs from five families. The off-springs were significantly younger at presentation and had significantly higher number of PCC/PGL. In conclusion, PCC/PGL are rare in patients with large VHL deletions and if occur are most likely to be solitary. Patients with bilateral PCC or multifocal PCC/PGL are least likely to have large VHL deletions. Our study also provides additional evidence for existence of the phenomenon of anticipation in VHL syndrome.

Entities:  

Keywords:  Anticipation; Large deletion; Pheochromocytoma; Von Hippel–Lindau syndrome

Mesh:

Substances:

Year:  2018        PMID: 29124493     DOI: 10.1007/s10689-017-0058-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  54 in total

1.  Telomere shortening is associated with genetic anticipation in Chinese Von Hippel-Lindau disease families.

Authors:  Xiang-Hui Ning; Ning Zhang; Teng Li; Peng-Jie Wu; Xi Wang; Xue-Ying Li; Shuang-He Peng; Jiang-Yi Wang; Jin-Chao Chen; Kan Gong
Journal:  Cancer Res       Date:  2014-07-01       Impact factor: 12.701

2.  Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome.

Authors:  Uri Tabori; Sonia Nanda; Harriet Druker; Jodi Lees; David Malkin
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

3.  Clinical features and natural history of von Hippel-Lindau disease.

Authors:  E R Maher; J R Yates; R Harries; C Benjamin; R Harris; A T Moore; M A Ferguson-Smith
Journal:  Q J Med       Date:  1990-11

4.  Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).

Authors:  Joseph A Blansfield; Lynda Choyke; Shane Y Morita; Peter L Choyke; James F Pingpank; H Richard Alexander; Geoffrey Seidel; Yvonne Shutack; Nargiza Yuldasheva; Michelle Eugeni; David L Bartlett; Gladys M Glenn; Lindsay Middelton; W Marston Linehan; Steven K Libutti
Journal:  Surgery       Date:  2007-12       Impact factor: 3.982

5.  Detection of large deletions in the VHL gene using a Real-Time PCR with SYBR Green.

Authors:  Andrew Ebenazer; Simon Rajaratnam; Rekha Pai
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

6.  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease.

Authors:  N G Ranen; O C Stine; M H Abbott; M Sherr; A M Codori; M L Franz; N I Chao; A S Chung; N Pleasant; C Callahan
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

7.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.

Authors:  P A Crossey; F M Richards; K Foster; J S Green; A Prowse; F Latif; M I Lerman; B Zbar; N A Affara; M A Ferguson-Smith
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

8.  Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.

Authors:  Jee-Soo Lee; Ji-Hyun Lee; Kyu Eun Lee; Jung Hee Kim; Joon Mo Hong; Eun Kyung Ra; Soo Hyun Seo; Seung Jun Lee; Man Jin Kim; Sung Sup Park; Moon-Woo Seong
Journal:  BMC Med Genet       Date:  2016-07-20       Impact factor: 2.103

9.  Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis.

Authors:  Hyun-Jung Cho; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

10.  Telomere length and genetic anticipation in Lynch syndrome.

Authors:  Nuria Seguí; Marta Pineda; Elisabet Guinó; Ester Borràs; Matilde Navarro; Fernando Bellido; Victor Moreno; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá; Laura Valle
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more
  3 in total

1.  A meta-analysis of different von Hippel Lindau mutations: are they related to retinal capillary hemangioblastoma?

Authors:  Fatemeh Azimi; Ali Aghajani; Golnaz Khakpour; Samira Chaibakhsh
Journal:  Mol Genet Genomics       Date:  2022-08-25       Impact factor: 2.980

2.  The Genotype-Phenotype Association of Von Hipple Lindau Disease Based on Mutation Locations: A Retrospective Study of 577 Cases in a Chinese Population.

Authors:  Jianhui Qiu; Kenan Zhang; Kaifang Ma; Jingcheng Zhou; Yanqing Gong; Lin Cai; Kan Gong
Journal:  Front Genet       Date:  2020-12-10       Impact factor: 4.599

3.  VHL mosaicism: the added value of multi-tissue analysis.

Authors:  Leslie E Oldfield; Jessica Grzybowski; Sylvie Grenier; Elizabeth Chao; Gregory S Downs; Kirsten M Farncombe; Tracy L Stockley; Ozgur Mete; Raymond H Kim
Journal:  NPJ Genom Med       Date:  2022-03-18       Impact factor: 8.617

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.